EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sphingosine‐1‐Phosphate Attenuates LPS‐Induced Inflammatory Cardiac Injury in Association With RASGRP1–S100A9–NLRP3 Signaling

Chaofu Yue iD, Qiaolin Li, Chunyan Li, Taoxian Yang, Xian Huang, Feng Yue, Qiuyu Long, Rong Li, Rong Lei iD, Qingsong Ma, Caimei Hu, Qian Yang und 4 weitere

Drug Development Research · 2026-11 · 87 (7)

DOI: 10.1002/ddr.70391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 22.09.2026. Verfasst von Chaofu Yue und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, Affiliated Qujing Hospital of Kunming Medical University, Qujing Central Hospital of Yunnan Province, Qujing, Yun …. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Lysophospholipids, Sphingosine, Guanine Nucleotide Exchange Factors. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Applied Basic Research Foundation of Yunnan Province, Qujing Central Hospital of Yunnan Province, Yunnan Province Longyun Expert Workstation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipopolysaccharide (LPS) induces endotoxemia‐associated inflammatory cardiac injury rather than classical viral or autoimmune myocarditis. Sphingosine‐1‐phosphate (S1P) regulates cardiovascular and immune responses, predominantly through S1P receptors, but whether it also modulates macrophage‐associated inflammatory signaling during LPS‐induced cardiac injury remains incompletely understood. This study investigated the role of the RASGRP1–S100A9–NLRP3 signaling axis in the cardioprotective effects of S1P. Transcriptomic and single‐cell RNA‐sequencing analyses were used to identify inflammation‐associated candidate genes and their cellular distribution. Male Sprague‐Dawley rats received a single intraperitoneal injection of LPS (8 mg/kg) followed by S1P treatment for 6 weeks. Histopathology, echocardiography, serum cardiac‐injury markers, oxidative‐stress indices, inflammatory cytokines, Western blotting, and cellular metabolic‐flux assays were evaluated. RAW264.7 macrophages were used for mechanistic cellular studies. RASGRP1 or NLRP3 overexpression and S100A9‐R101Q mutation were used to assess functional contributions. Molecular docking and molecular‐dynamics simulations were complemented by SPR, MST, CETSA, DARTS, and Co‐IP assays to evaluate S1P–RASGRP1 target engagement and pathway‐associated protein interactions. Bioinformatic analyses identified RASGRP1 as a macrophage‐enriched, inflammation‐associated hub gene. In LPS‐treated rats, S1P reduced myocardial inflammatory injury and collagen deposition, improved ejection fraction and fractional shortening, and decreased cardiac‐injury, oxidative‐stress, and inflammatory markers. In RAW264.7 macrophages, S1P attenuated inflammatory and oxidative‐stress responses, restored oxidative phosphorylation and glycolytic capacity, and reduced the abundance of RASGRP1, S100A9, NLRP3, and ASC. SPR and MST supported a concentration‐dependent biophysical interaction between S1P and RASGRP1; CETSA and DARTS provided complementary target‐stability evidence. The molecular‐dynamics trajectory showed substantial rearrangement of S1P from the starting pose before reaching a plateau and therefore supports conformational sampling rather than preservation of the original docked pose. Co‐IP supported protein associations within the proposed inflammatory network. RASGRP1 or NLRP3 overexpression attenuated several S1P‐associated protective effects. The S100A9‐R101Q mutation also weakened several S1P‐associated protective responses. SPR indicated a lower apparent dissociation constant for R101Q than for WT S100A9 after model‐specific fitting, which is consistent with stronger or more persistent NLRP3 binding rather than loss of the S100A9–NLRP3 interaction. S1P mitigates LPS‐induced inflammatory cardiac injury in association with altered macrophage RASGRP1–S100A9–NLRP3 signaling. Biophysical and target‐stability assays support direct engagement of RASGRP1 by S1P. However, these findings do not establish RASGRP1 as the sole mediator of S1P activity, exclude contributions from canonical S1P receptor signaling, or demonstrate a strictly linear RASGRP1–S100A9–NLRP3 signaling cascade. Because the LPS model primarily represents endotoxemia‐associated inflammatory cardiac injury, extrapolation of these findings to classical viral or autoimmune myocarditis should be made with caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinLysophospholipidsSphingosineGuanine Nucleotide Exchange FactorsCalgranulin BHeart InjuriesAnimalsMaleRatsRats, Sprague-DawleySignal TransductionLipopolysaccharidesMiceRAW 264.7 CellsInflammationMolecular Docking Simulation

Stichwörter der Autor:innen

NLRP3 inflammasomecardioprotectioninflammatory cardiac injurylipopolysaccharidesphingosine‐1‐phosphate (S1P)

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinLysophospholipidssphingosine 1-phosphateLipopolysaccharidesSphingosineGuanine Nucleotide Exchange FactorsCalgranulin BNlrp3 protein, rat

Autor:innen und Institutionen

  • Department of Intensive Care Unit, Affiliated Qujing Hospital of Kunming Medical University, Qujing Central Hospital of Yunnan Province, Qujing, Yun Nan, China.
  • Department of Endocrinology and Metabolism, Affiliated Qujing Hospital of Kunming Medical University, Qujing Central Hospital of Yunnan Province, Qujing, Yun Nan, China.
  • Nursing Department, Affiliated Qujing Hospital of Kunming Medical University, Qujing Central Hospital of Yunnan Province, Qujing, Yun Nan, China.

ORCID-Profile: Chaofu Yue, Rong Lei

Förderung

  • Applied Basic Research Foundation of Yunnan Province
  • Qujing Central Hospital of Yunnan Province
  • Yunnan Province Longyun Expert Workstation
  • Special Project Fund for Nursing, Kunming Medical University

Zitieren

APA

Yue, C., Li, Q., Li, C., Yang, T., Huang, X., Yue, F., Long, Q., Li, R., Lei, R., Ma, Q., Hu, C., Yang, Q., Yan, Y., Liu, Y., Yan, Q., & Yang, M. (2026). Sphingosine‐1‐Phosphate Attenuates LPS‐Induced Inflammatory Cardiac Injury in Association With RASGRP1–S100A9–NLRP3 Signaling. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70391

Vancouver

Yue C, Li Q, Li C, Yang T, Huang X, Yue F, et al. Sphingosine‐1‐Phosphate Attenuates LPS‐Induced Inflammatory Cardiac Injury in Association With RASGRP1–S100A9–NLRP3 Signaling. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70391

BibTeX
@article{Yue2026,
  author = {Yue, Chaofu and Li, Qiaolin and Li, Chunyan and Yang, Taoxian and Huang, Xian and Yue, Feng and Long, Qiuyu and Li, Rong and Lei, Rong and Ma, Qingsong and Hu, Caimei and Yang, Qian and Yan, Yongjun and Liu, Yuan and Yan, QinYong and Yang, Mei},
  title = {Sphingosine‐1‐Phosphate Attenuates LPS‐Induced Inflammatory Cardiac Injury in Association With RASGRP1–S100A9–NLRP3 Signaling},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {7},
  doi = {10.1002/ddr.70391}
}
Kostenlos starten →